Chemical structure of molecule compound 24 LRRK2

LRRK2 kinase inhibitor

preclinical, brain-penetrant

from rational HTL and structure-guided opt.

Journal of Medicinal Chemistry

Merck & Co., Boston, MA

LRRK2 is a target of interest for Parkinson’s disease (e.g. DNL-151), but development had been slowed by concerns about potential lung toxicity of LRRK2 inhibitors. A Phase I study…

 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.